Market eyes CAR-T pricing as China grants second approval in September
Danni Yin · 10/22/2021
Chinese regulators gave their nod to the second domestic CAR-T cell therapy in three months, raising concerns in the market about how companies will make these expensive, advanced treatments more accessible to Chinese patients. The PD-1 frenzy also continued with PD-1 biosimilars.
READ MORE

Latest Articles

Sinotau closes $50M in Series D+ to advance radiopharmaceuticals, and more - Daily news
Elise Mak · 2 hours ago
Sinotau Pharmaceutical Group said it closed a Series D+ round to raise RMB320 million ($50 million) to support clinical research and development of radiopharmaceuticals, and more news from Luoxin Pharmaceutical, Zai Lab and Antengene.
News
Market eyes CAR-T pricing as China grants second approval in September
Danni Yin · 6 hours ago
Chinese regulators gave their nod to the second domestic CAR-T cell therapy in three months, raising concerns in the market about how companies will make these expensive, advanced treatments more accessible to Chinese patients. The PD-1 frenzy also continued with PD-1 biosimilars.
China Deals Tracker
Exclusive: Former FDA official calls Aduhelm approval heroic and clarifies misconceptions
Minhua Chu · Yesterday
Why was the approval decision so controversial? Has the FDA lowered its normal standards during the review? Wang clarified the questions about the review with data from the published FDA reports.
Feature
Ascentage publishes preclinical data of EED inhibitor in Journal of Medicinal Chemistry, and more - Daily news
Elise Mak · Yesterday
After publishing preclinical data of EEDi-5273 in the Journal of Medicinal Chemistry, Ascentage Pharma hopes to move what it believes to be a best-in-class drug to the clinic soon, and more news from Huadong Medicine, Huashen Intelligent Pharma and Lianbio.
News
Berry Oncology is primed to compete with Grail and Thrive in early cancer screening
Elise Mak · 2 days ago
With its HIFI screening technology, Berry Oncology has developed one single test to early screen for liver, lung, gastric, colorectal, esophageal and pancreatic cancers. Results unveiled at IBIWS last week showed an overall sensitivity of 87.6%, specificity of 99.1% and overall Tissue of Origin precision in 82% of positive cancers.
Feature
China approves Chipscreen's type 2 diabetes drug chiglitazar, and more - Daily news
Elise Mak · 2 days ago
The NMPA has approved Chipscreen Biosciences's chiglitazar as a treatment for type 2 diabetes, and more news from Legend Biotech and CTTQ.
News
WuXi Apptec's cell and gene therapy unit opens facility in Shanghai, and more - Daily news
Elise Mak · 3 days ago
WuXi Advanced Therapies (WuXi ATU), a WuXi AppTec subsidiary focused on cell and gene therapy, said its new process development and commercial manufacturing facility opened in Shanghai, and more news from Bio-Thera Solutions, Huahui Health and Innovent.
News
BeiGene to "vigorously" contest BMS-Celgene's termination of Abraxane pact, and more - Daily news
Elise Mak · 4 days ago
In an ongoing dispute surrounding Abraxane (paclitaxel), a drug that BeiGene licensed from BMS' subsidiary Celgene in 2017, the Chinese drugmaker said it intends to contest "vigorously" the termination proposed by its partner, and more news from GV20 Oncotherapy, HANSOH Pharma, Hengrui Pharma and Anticancer Bioscience.
News
Takeda's Takecab cleared as maintenance therapy of reflux esophagitis in China, and more - Daily news
Elise Mak · 6 days ago
Takeda's Takecab (vonoprazan), an orally bioavailable potassium-competitive acid blocker (P-CAB), was approved for a new indication in China, and more news from Boan Biotech and Eubulus Biotherapeutics.
News
September fundraising puts cell therapy and immuno-oncology in the spotlight
PharmaDJ · 7 days ago
Chinese drugmakers closed 33 financing rounds in September, raising over $1.05 billion. Oncolytic virus therapies developer Virogin Biotech and two CAR-T therapy developers were the biggest fundraisers.
China Deals Tracker
Copyright © 2016-2021 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement